



Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study

Sebastiano Leone¹ · Patrizia Lorenzini² · Alessandro Cozzi-Lepri³ · Giancarlo Orofino⁴ · Dario Bernacchia⁵ · Antonella Castagna⁶ · Marianna Menozzi⁷ · Giovanni Guaraldi⁷ · Giordano Madeddu⁸ · Antonio Di Biagio⁹ · Massimo Puoti¹⁰ · Andrea Gori^{11,12} · Antonella d'Arminio Monforte¹³ · for the ICONA Foundation Study Group

Received: 21 May 2019 / Accepted: 14 June 2019 / Published online: 22 June 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract

To investigate the association between diabetes and HCV infection in persons living with HIV and to determine the impact of diabetes on the occurrence of serious liver events (SLEs) and liver-related deaths (LRDs) among HIV/HCV-co-infected patients. Patients were included if they had at least one follow-up visit. In a cross-sectional analysis among all HIV patients, we have investigated the association between diabetes and HCV infection. A further longitudinal analysis was performed in the population of HIV/HCV-co-infected free from SLE with FIB-4 index < 3.25 at baseline, using the following endpoints: (A) first event between SLE and LRD; (B) liver fibrosis progression defined as the first of two consecutive FIB-4 > 3.25; (C) first event between SLE, LRD, and liver fibrosis progression. Data from 15,571 HIV patients were analyzed: 2944 (18.9%) were HCV-Ab positive, and 739 (4.7%) presented a diagnosis of diabetes at their last follow-up. Among HIV/HCV-co-infected population, 107 patients had a diagnosis of diabetes. Viremic HCV-co-infected patients had 3-fold risk of diabetes onset than HCV-uninfected patients. On HIV/HCV-co-infected population, 85 SLEs/LRDs occurred over 20,410 person-years of follow-up (PYFU), for an incidence rate of 4.2/1000 PYFU (95%CI 3.4–5.2). Diabetic patients had 3-fold risk of pooled SLE and LRD than patients without diabetes. Furthermore, viremic HCV infection was independently associated with a higher risk of SLE/LRD (aIRR 3.35 [95%CI 1.14–9.83]). In HIV-infected patients, viremic HCV co-infection is a strong predictor of diabetes. Among HIV/HCV-co-infected population, diabetic patients showed an increased risk of SLE/LRD compared with those without diabetes.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s10096-019-03618-8>) contains supplementary material, which is available to authorized users.

✉ Sebastiano Leone
sebastianoleone@yahoo.it

¹ Division of Infectious Diseases, Department of Internal Medicine, San Giuseppe Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy

² National Institute for Infectious Diseases L. Spallanzani, Rome, Italy

³ Institute for Global Health, University College London, London, UK

⁴ Infectious Diseases Unit A, Amedeo di Savoia Hospital, Turin, Italy

⁵ Infectious Diseases Unit, ASST Fatebenefratelli-Sacco, DIBIC 'L. Sacco', University of Milan, Milan, Italy

⁶ Infectious Diseases Department, IRCCS San Raffaele Scientific Institute & Vita-Salute University, Milan, Italy

⁷ Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy

⁸ Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy

⁹ Infectious Diseases Unit, Policlinico San Martino Hospital, Genoa, Italy

¹⁰ Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

¹¹ Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

¹² Department of Pathophysiology and Transplantation, School of Medicine and Surgery, University of Milan, Milan, Italy

¹³ Clinic of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy

Keywords HIV/HCV co-infection · Serious liver events · Liver-related deaths · Diabetes mellitus

Introduction

Combination antiretroviral therapy (cART) has significantly reduced the mortality and morbidity among HIV-infected patients [1]. The improvement in AIDS-related survival rates resulted in an increase of non-HIV-related deaths, including liver-related deaths and especially those due to chronic hepatitis C (CHC) [2]. HIV/HCV-co-infected patients have an increased risk of liver fibrosis progression compared with those with HCV mono-infection [3]. Furthermore, HCV infection seems to be associated with an increased incidence rate (IR) of diabetes mellitus, which itself plays a major role in the acceleration of liver disease and in the increased probability of liver-related complications. Indeed, glucose abnormalities, including insulin resistance and diabetes, are associated with an increased occurrence of severe liver fibrosis due to increased oxidative stress and inflammatory cytokine secretion [4]. The aim of our study was, firstly, to investigate the association between diabetes and HCV infection in the HIV population and, secondly, to determine the risk factors of serious liver events (SLEs) and liver-related deaths (LRDs) and fibrosis progression among HIV/HCV-co-infected patients enrolled in a large Italian cohort.

Patients and methods

Study participants

Patients were selected from the Italian Cohort of Antiretroviral-Naïve patients (ICONA) Foundation Cohort Study, which is a multicenter prospective observational study of HIV-infected patients who enter clinical care when still antiretroviral-therapy naïve that was set up in April 1997. Demographics, medication, and disease history are recorded using an electronic data collection form (www.icona.org) at enrollment and updated on a 6-monthly basis. Cohort details have been previously reported [5]. For the purpose of this study, all patients free from SLE at baseline, enrolled since January 1997 up to December 2018, were included if they had at least one follow-up visit.

Study outcomes

The main outcome is to explore the association between diabetes and HCV infection in the HIV population. Secondly, we investigated the predictors for SLE and LRD occurrence in HIV/HCV patients. Furthermore, we evaluated the impact of

diabetes on the liver fibrosis progression in the co-infected population (Fig. 1).

Definitions

HCV-infected population included all subjects with at least one HCV-Ab positive and/or HCV-RNA positive test. All anti-HCV-treated (interferon and direct-acting antiviral based regimens) and anti-HCV-untreated patients were included. Type 2 diabetes was defined at the time of the first of two consecutive fasting blood glucose levels of > 126 mg/dL or use of antidiabetic drugs. SLE included the following complications: ascites, gastrointestinal bleeding, hepatic encephalopathy, hepatocellular carcinoma (HCC), hepatopulmonary syndrome, hepatorenal syndrome, spontaneous bacterial peritonitis. LRD was defined as death associated with liver cirrhosis or its complications. Liver fibrosis was defined using the FIB-4 score and was calculated by Sterling's formula: $\text{age (years)} \times \text{AST (U/L)} / (\text{platelets (10}^9\text{/L)} \times (\text{ALT (U/L)})^{1/2})$. Advanced liver fibrosis was defined by two consecutive FIB-4 score ≥ 3.25 [6]. AIDS diagnosis was defined using the 1993 Centers for Disease Control and Prevention criteria [7]. Body mass index (BMI) was calculated according to the following formula: $(\text{weight in kilograms}) / (\text{height in meters}^2)$. Alcohol consumption was categorized into 3 groups: abstainers, occasionally, and everyday consumers.

Statistical analysis

Descriptive statistics were expressed as median and interquartile range (IQR) for continuous variables or as proportions for categorical variables. For the analyses, database was frozen on December 2018. Two different analyses were performed. Firstly, a cross-sectional analysis was performed to investigate, in persons living with HIV, the association between diabetes and HCV-Ab and HCV-RNA positivity, by means of multivariable logistic regression. Patients were observed at their last follow-up. A second longitudinal analysis was performed in the population of HIV/HCV-co-infected patients free from SLE and with FIB-4 index < 3.25 at baseline, using the following endpoints: (A) first event between SLE and LRD; (B) liver fibrosis progression defined as the first of two consecutive FIB-4 > 3.25; (C) first event between SLE, LRD, and liver fibrosis progression. The baseline of this analysis was the date of first HCV-Ab positivity. Patients were followed until onset of first SLE or LRD or last available clinical follow-up, whichever occurred first. Type 2 diabetes diagnosis was used as a time-dependent covariate. The IR was calculated as the number of events over person-years of




Fig. 1 Flowchart of the patients included in the study

follow-up (PYFU) and expressed per 1000 PYFU. The risk of the outcome in patients with diabetes was estimated by means of Poisson regression multivariable model, adjusting for main confounders. The following covariates at baseline were explored at univariable analysis: gender, age, nationality, mode of HIV transmission, duration of HIV infection, HBV co-infection, AIDS diagnosis, BMI, smoke status, alcohol use, blood hypertension, nadir CD4+ cell count, CD4+ cell count and HIV-RNA at the baseline, FIB-4, total and HDL cholesterol, triglycerides, cART exposure, HCV-RNA and HCV genotype. All models were adjusted for all variables except for HCV genotype. In particular, age was not retained as covariate when the outcome included FIB-4. All analyses were performed using the software STATA 15.1.

Ethics

The ICONA study was approved by the institutional review boards or ethics committees of each clinical site. All patients provided their written informed consent at the enrollment. All procedures of the study were performed in accordance with the 1964 Helsinki Declaration and its later amendments (October 2013 revision).

Results

Patients' characteristics

We included 15,571 HIV patients, and among these, 2944 (18.9%) individuals were HCV-Ab positive. Table 1 shows the main characteristics of the study population. In brief, the median age was 43 (IQR 36–51) years; 11,927 (76.6%) patients were male; 2573 (16.5%) patients became HIV-infected through injection drug use (IDU), 5926 (38.1%) patients were infected through homosexual contact, and 5981 (38.4%) through heterosexual contact; and 754 (4.8%) patients were found to be HBsAg positive. Median (IQR) CD4+ cell count at baseline was 591 (387–820) cells/mm³, and median (IQR) HIV-RNA at baseline was 1.6 (0–2.7) log₁₀ copies/mL; 2136

(13.7%) patients had an AIDS diagnosis at baseline. Almost all of the patients (97.1%) had available baseline FIB-4 index: 11,767 (75.6%) patients had a FIB-4 < 1.45, 2579 (16.6%) patients had an index between 1.45 and 3.25, and 778 (5.0%) patients had a FIB-4 > 3.25, respectively.

Diabetes

Over 15,571 HIV-infected patients, 739 (4.7%) presented a diagnosis of diabetes at their last follow-up. Among HIV/HCV-co-infected population, 107 patients had a diagnosis of diabetes (29 patients were diabetic at baseline, and 78 patients developed diabetes during the follow-up). Viremic HCV co-infection was independently associated with diabetes diagnosis (adjusted odds ratio [aOR] 3.35 [95%CI 2.38–4.71]). Other factors independently associated with diabetes diagnosis were older age (45–55 years old: aOR 1.79 [95%CI 1.43–2.24] and > 55 years old: aOR 2.15 [95%CI 1.64–2.82] vs < 45 years old, respectively), higher BMI values (BMI ≥ 30: aOR 4.93 [95%CI 2.71–8.98], respectively), HIV-RNA detectable at baseline (≤ 50 copies/mL: aOR 3.08 [95%CI 2.25–4.22] and > 50 copies/mL: aOR 5.79 [95%CI 4.17–8.03], respectively), higher FIB-4 score (FIB-4 1.45–3.25: aOR 1.32 [95%CI 1.05–1.65] and FIB-4 > 3.25: aOR 1.48 [95%CI 1.07–2.03], respectively), hypertension (aOR 2.33 [95%CI 1.83–2.96]), hypercholesterolemia (aOR 1.29 [95%CI 1.04–1.59]), and hypertriglyceridemia (aOR 3.66 [95%CI 2.99–4.48]) (Table 1).

Risk of SLE/LDR

Two thousand six hundred seventy HCV-Ab-positive subjects with a FIB-4 < 3.25 were selected for this analysis and observed for 20,410 PYFU; 85 SLEs/LRDs occurred. The IR was 4.2/1000 PYFU (95%CI 3.4–5.2). In detail, we observed 65 SLEs: 19 (29.2%) ascites, 10 (15.4%) hepatic encephalopathy, 9 (13.8%) HCC, 8 (12.3%) gastrointestinal bleeding, 3 (4.6%) hepatorenal syndrome, and 16 (24.6%) hepatic failure not specified; moreover, there were 20 (23.5%) LRDs. Diabetic patients had 3-fold IR of pooled SLE and LRD than patients without diabetes (IR 12.1/1000 [95%CI 5.8–25.4] and IR 3.9/1000 [95%CI 3.2–4.9], respectively). Diabetes was independently associated with higher risk of SLEs/LRDs (adjusted incidence risk ratio [aIRR] 3.06 [95%CI 1.30–7.19]). Additional predictors were the following: female gender, HBV co-infection, AIDS diagnosis, viremic HCV co-infection, and higher FIB-4 at baseline (Table 2). When the composite outcome SLE/LRD/FIB-4 > 3.25 was analyzed, we found 424 events over 17,988 PYFU, corresponding to an IR of 2.4 (95%CI 2.1–2.6) per 100 PYFU. No differences in IR between diabetic and non-diabetic patients were observed (IR 2.8 [95%CI 1.5–5.0] and IR 2.3 [95%CI 2.1–2.6], respectively). Moreover, longer HIV history (> 10 years: aIRR 1.34

Table 1 Main baseline characteristics and predictors of type 2 diabetes onset

		<i>n</i> (%)	OR	95%CI	<i>p</i> value	aOR	95%CI	<i>p</i> value
Gender	Male	11,927 (76.6%)	1.00			1.00		
	Female	3644 (23.4%)	0.61	0.50–0.74	0.000	0.68	0.52–0.88	0.003
Age	< 45	9150 (58.8%)	1.00			1.00		
	45–55	4163 (26.8%)	1.88	1.59–2.24	0.000	1.79	1.43–2.24	0.000
	> 55	2252 (14.5%)	2.52	2.08–3.05	0.000	2.15	1.64–2.82	0.000
Mode of HIV transmission	Injection drug use	2573 (16.5%)	1.00			1.00		
	Heterosexual contact	5981 (38.4%)	1.25	1.03–1.50	0.023	0.87	0.62–1.23	0.436
	Men having sex with men	5926 (38.1%)	0.50	0.42–0.61	0.000	0.62	0.48–0.79	0.000
	Others/unknown	1091 (7.0%)	0.89	0.67–1.20	0.457	0.70	0.48–1.03	0.067
Nationality	Natives	12,130 (77.9%)	1.00			1.00		
	Migrants	3441 (22.1%)	0.46	0.36–0.57	0.000	0.35	0.25–0.49	0.000
Years of HIV infection	0–5	7527 (48.3%)	1.00			1.00		
	5–10	3759 (24.1%)	0.47	0.38–0.58	0.000	0.63	0.48–0.82	0.000
	> 10	4261 (27.4%)	0.75	0.63–0.89	0.001	0.64	0.50–0.83	0.001
	Missing	24 (0.2%)	NC			NC		
HBsAg	Negative	12,896 (82.8%)	1.00			1.00		
	Positive	754 (4.8%)	1.03	0.71–1.50	0.871	1.05	0.70–1.57	0.830
	Unknown	1921 (12.3%)	3.07	2.59–3.64	0.000	1.04	0.68–1.59	0.862
BMI	< 18.5	529 (3.4%)	0.99	0.58–1.69	0.976	1.27	0.72–2.23	0.413
	18.5–24.9	7977 (51.2%)	1.00			1.00		
	25–29.9	3307 (21.2%)	1.63	1.32–2.01	0.000	1.68	0.94–3.00	0.081
	≥ 30	881 (5.7%)	4.70	3.69–5.98	0.000	4.93	2.71–8.98	0.000
	Missing	2877 (18.5%)	3.09	1.82–5.25	0.000	0.89	0.48–1.66	0.719
AIDS diagnosis	No	13,435 (86.3%)	1.00			1.00		
	Yes	2136 (13.7%)	1.38	1.13–1.67	0.001	1.06	0.82–1.35	0.670
CD4 nadir (cells/mm ³)	> 200	5180 (33.3%)	1.00			1.00		
	0–200	10,175 (65.4%)	0.54	0.46–0.64	0.000	0.82	0.66–1.02	0.081
	Missing	216 (1.4%)	68.83	48.49–97.72	0.000	NC		
CD4 at baseline (cells/mm ³)	0–500	5874 (37.7%)	1.00			1.00		
	> 500	9465 (60.8%)	0.59	0.50–0.70	0.000	1.00	0.81–1.25	0.965
	Missing	232 (1.5%)	68.39	49.12–95.21	0.000	NC		
HIV-RNA at baseline (copies/mL)	Not detected	4873 (31.8%)	1.00			1.00		
	≤ 50 detected	5470 (35.7%)	3.60	2.66–4.86	0.000	3.08	2.25–4.22	0.000
	> 50 detected	4970 (32.5%)	5.55	4.14–7.44	0.000	5.79	4.17–8.03	0.000
HCV-Ab	Negative	11,206 (72.0%)	1.00			NI		
	Positive	2944 (18.9%)	1.66	1.40–1.96	0.000			
	Unknown	1421 (9.1%)	0.63	0.46–0.88	0.006			
HCV-Ab & HCV-RNA	HCV-Ab negative	11,206 (72.0%)	1.00			1.00		
	HCV-Ab positive and HCV-RNA negative	709 (4.6%)	0.54	0.33–0.87	0.013	0.59	0.33–1.09	0.091
	HCV-Ab positive and HCV-RNA positive	1242 (8.0%)	2.98	2.45–3.61	0.000	3.35	2.38–4.71	0.000
	HCV-Ab positive and HCV-RNA unknown	993 (6.4%)	0.96	0.70–1.33	0.823	0.67	0.42–1.05	0.082
	HCV-Ab unknown	1421 (9.1%)	0.63	0.46–0.88	0.006	0.47	0.27–0.80	0.005
FIB-4 index	< 1.45	11,767 (75.6%)	1.00			1.00		
	1.45–3.25	2579 (16.6%)	2.49	2.04–3.02	0.000	1.32	1.05–1.65	0.018
	> 3.25	778 (5.0%)	4.01	3.09–5.22	0.000	1.48	1.07–2.03	0.016
	Missing	447 (2.9%)	27.92	22.43–34.75	0.000	1.97	1.15–3.38	0.014
Blood hypertension	No	14,217 (91.3%)	1.00			1.00		

Table 1 (continued)

		<i>n</i> (%)	OR	95%CI	<i>p</i> value	aOR	95%CI	<i>p</i> value
Total cholesterol (mg/dL)	Yes	1354 (8.7%)	3.16	2.62–3.80	0.000	2.33	1.83–2.96	0.000
	≤ 200	10,351 (66.5%)	1.00			1.00		
	> 200	4577 (29.4%)	1.55	1.29–1.86	0.000	1.29	1.04–1.59	0.018
HDL cholesterol (mg/dL)	Missing	643 (4.1%)	17.61	14.45–21.46	0.000	4.78	2.32–9.85	0.000
	> 40M/> 60F	3911 (25.1%)	1.00					
	≤ 40M/≤ 60F	9793 (63.9%)	1.77	1.38–2.26	0.000	NI		
Triglycerides (mg/dL)	Missing	1867 (12.0%)	9.88	7.67–12.73	0.000			
	≤ 150	10,575 (67.9%)	1.00			1.00		
	> 150	4379 (28.1%)	4.88	4.06–5.86	0.000	3.66	2.99–4.48	0.000
Alcohol use	Missing	617 (4.0%)	30.71	24.61–38.32	0.000	1.09	0.49–2.42	0.831
	Abstainers	6626 (42.6%)	1.00			1.00		
	Occasionally	3989 (25.6%)	0.66	0.52–0.84	0.001	0.73	0.56–0.95	0.017
	Everyday	1211 (7.8%)	0.95	0.68–1.32	0.750	0.73	0.51–1.05	0.088
Smokers	Missing	3745 (24.0%)	2.64	2.23–3.12	0.000	1.50	1.19–1.88	0.001
	Yes	6710 (43.1%)	1.00					
	No	7886 (50.7%)	1.09	0.93–1.27	0.273	NI		
	Missing	975 (6.3%)	1.35	1.01–1.79	0.042			

NI not included in the model, NC not calculable

[95%CI 1.05–1.71], HBV co-infection (aIRR 1.90 [95%CI 1.31–2.76]), AIDS diagnosis (aIRR 1.71 [95%CI 1.22–2.39]), viremic HCV co-infection (aIRR 2.88 [95%CI 1.80–4.62]), higher FIB-4 at baseline (aIRR 2.71 [95%CI 2.38–3.10]), and everyday alcohol use (aIRR 2.04 [95%CI 1.19–3.50]), but not diabetes (aIRR 0.92 [95%CI 0.49–1.70]) were independently associated with higher risk of SLE/LRD/FIB-4 > 3.25 occurrence (Table S1).

Liver fibrosis progression

Multivariable analysis showed that HBV co-infection, AIDS diagnosis, viremic HCV co-infection, higher FIB-4 (per 1 point higher) at baseline, and everyday alcohol use were independently associated with liver fibrosis progression. Conversely, diabetes was not associated with risk of liver fibrosis progression (aIRR 0.94 [95%CI 0.51–1.75]) (Table 2).

Discussion

In this analysis from the ICONA cohort, we evaluated the association between HCV infection and diabetes and further the risk of SLE and LRD in HIV/HCV-co-infected patients with diabetes. We found that HCV infection was associated with a 3-fold increased risk of diabetes onset than uninfected patients. These results confirm those observed by others [8–12]. Among HCV-Ab-positive patients, we observed that the probability of diabetes occurrence was independently associated with viremic HCV infection, whereas, although it

does not reach significance, aviremic subjects had a 41% lower risk of developing diabetes. Similarly, in a previous ICONA study, De Luca et al. found that HCV-Ab-positive/HCV-RNA-positive status was independently associated with a higher incidence (adjusted relative rate [aRR] 1.73 [95%CI 1.08–2.78]) and prevalence (aOR 2.49 [1.08–5.74]) of diabetes, whereas HCV-Ab-positive/HCV-RNA-negative status was not [13]. Furthermore, we found that diabetes onset was independently associated with the liver fibrosis stage. These results are in line with those observed in other HIV cohorts [14, 15]. On this point, in a large French multicenter cohort, cirrhotic patients had a 2-fold increased risk of developing diabetes but not patients with CHC [15].

Overall, diabetic patients showed a significant increased incidence of major liver/renal-related events compared with non-diabetic patients. We found that ascites was the leading liver-related complication observed among our HCV/HIV-co-infected patients. Diabetes is a well-recognized risk factor for the development of ascites in cirrhotic patients [16]. Furthermore, cirrhotic patients with diabetes and refractory ascites had a poor outcome compared with those without diabetes. On this point, a retrospective French study that investigated the predictors of prognosis in cirrhotic patients with refractory ascites found that the probability of survival at 1 and 2 years in diabetic patients was 32% and 18%, respectively, and 62% and 58%, respectively, in non-diabetic patients [17]. Moreover, we observed that HCC accounted for 12% of all SLEs. Several studies confirmed that diabetes is an independent and strong predictor for the

Table 2 Adjusted incidence rate ratios (IRR) of SLE/LDR and FIB > 3.25 estimated by means of Poisson regression

		SLE/LDR			FIB > 3.25		
		aIRR	95%CI	<i>p</i> value	aIRR	95%CI	<i>p</i> value
Diabetes	No	1.00			1.00		
(Time-updated)	Yes	3.06	1.30–7.19	0.010	0.94	0.51–1.75	0.848
Gender	Male	1.00			1.00		
	Female	2.05	1.24–3.38	0.005	0.71	0.54–0.92	0.012
Mode of HIV transmission	Heterosexual contact	1.00			1.00		
	Injection drug use	2.00	0.73–5.50	0.180	1.20	0.83–1.73	0.335
	Men having sex with men	NC	–	–	0.36	0.17–0.77	0.008
	Others/unknown	2.94	0.62–14.01	0.176	0.92	0.42–2.03	0.838
Nationality	Natives	1.00			1.00		
	Migrants	NC	–	–	0.64	0.28–1.44	0.278
Years of HIV infection	0–5	1.00			1.00		
	5–10	1.29	0.70–2.40	0.418	1.30	1.00–1.69	0.052
	> 10	1.46	0.85–2.52	0.170	1.26	0.98–1.62	0.069
	Missing	NC	–	–	NC	–	–
HBsAg	Negative	1.00			1.00		
	Positive	5.78	3.17–10.53	0.000	1.75	1.18–2.60	0.005
	Unknown	0.56	0.17–1.82	0.336	1.09	0.75–1.58	0.636
BMI at baseline	< 18.5	1.01	0.35–2.89	0.990	0.88	0.51–1.49	0.624
	18.5–24.9	1.00			1.00		
	25–29.9	0.80	0.24–2.67	0.715	0.56	0.31–1.00	0.05
	≥ 30	2.13	0.53–8.50	0.284	1.38	0.68–2.80	0.367
	Missing	1.63	0.49–5.43	0.429	1.04	0.57–1.91	0.887
AIDS diagnosis	No	1.00			1.00		
	Yes	2.27	1.14–4.53	0.020	1.67	1.18–2.35	0.004
CD4 nadir (cell/mm ³)	> 200	1.00			1.00		
	0–200	0.87	0.43–1.76	0.690	0.82	0.59–1.15	0.254
	Missing	NC	–	–	NC	–	–
CD4 at baseline (cell/mm ³)	0–350	1.00			1.00		
	351–500	0.77	0.37–1.58	0.473	1.12	0.81–1.54	0.484
	> 500	0.76	0.40–1.42	0.382	1.22	0.92–1.63	0.172
	Missing	NC	–	–	NC	–	–
HIV-RNA at baseline (cp/mL)	≤ 200	1.00			1.00		
	> 200	0.80	0.29–2.21	0.667	1.50	0.88–2.55	0.136
	Missing	1.62	0.40–6.50	0.495	2.79	1.38–5.65	0.004
HCV-RNA	Negative	1.00			1.00		
	Positive	3.35	1.14–9.83	0.028	2.74	1.71–4.40	0.000
	Unknown	8.06	2.69–24.20	0.000	3.27	1.98–5.38	0.000
Smokers	Yes	1.00			1.00		
	No	0.78	0.41–1.47	0.437	0.89	0.66–1.18	0.408
	Missing	0.55	0.30–1.01	0.055	1.08	0.83–1.40	0.574
ARV experienced	No	1.00			1.00		
	Yes	0.74	0.20–2.75	0.652	1.12	0.66–1.92	0.675
FIB-4 index at baseline, per 1 point higher		2.01	1.49–2.71	0.000	2.77	2.42–3.18	0.000
Blood hypertension	No	1.00			1.00		
	Yes	0.95	0.46–1.95	0.883	1.13	0.82–1.56	0.441
Total cholesterol (mg/dL)	≤ 200	1.00			1.00		

Table 2 (continued)

		SLE/LDR			FIB > 3.25		
		aIRR	95%CI	<i>p</i> value	aIRR	95%CI	<i>p</i> value
HDL cholesterol (mg/dL)	> 200	0.28	0.04–2.13	0.217	0.58	0.33–1.02	0.06
	Missing	0.94	0.34–2.65	0.914	0.60	0.37–0.98	0.041
	> 40M > 60F	1.00			1.00		
	≤ 40M ≤ 60F	NC	–	–	1.99	0.88–4.52	0.1
Triglycerides (mg/dL)	Missing	NC	–	–	3.04	1.34–6.90	0.008
	≤ 150	1.00			1.00		
	> 150	0.92	0.41–2.09	0.846	0.95	0.67–1.36	0.782
Alcohol use	Missing	0.82	0.32–2.09	0.680	1.09	0.69–1.72	0.724
	Abstainers	1.00			1.00		
	Occasionally	0.69	0.14–3.26	0.636	1.68	0.98–2.86	0.058
	Everyday	1.99	0.52–7.65	0.319	2.06	1.18–3.59	0.011
	Missing	1.24	0.61–2.51	0.553	1.37	0.99–1.90	0.057

NI not included in the model, *NC* not calculable

development of HCC. Moreover, diabetes negatively impacts on survival outcomes (overall survival rate and disease-free survival rate) in patients with HCC [18, 19].

In a multivariable model, we found that patients with diabetes had a 3-fold increased risk of pooled SLE and LRD than those without diabetes. Our findings are consistent with those from other observational studies evaluating the prognostic impact of diabetes in patients with HCV infection. In a French retrospective study, including HCV-monoinfected and HIV/HCV-co-infected cirrhotic patients, Elkrief et al. found that baseline diabetes was an independent prognostic factor for death and transplantation-free survival (hazard ratio [HR] 1.34 [95%CI 1.03–1.73]). Baseline diabetes was also associated with an increased risk of liver-related complications, such as ascites (HR 1.63 [95%CI 0.99–2.70]), renal dysfunction (HR 2.35 [95%CI 1.32–4.20]), bacterial infections (HR 2.10 [95%CI 1.23–3.59]), and HCC (HR 1.94 [95%CI 1.13–3.33]), during the follow-up [20]. Similarly, a large North-American retrospective study found that diabetic HIV/HCV-co-infected patients had a 2-fold increased risk of developing liver decompensation (HR 1.88 [95%CI 1.38–2.56]) [21]. In addition, in an Asiatic study with a long follow-up including only CHC monoinfected patients, Huang et al. found that new-onset diabetes was independently associated with development of cirrhosis (HR 2.50 [95%CI 1.61–3.90]) and liver decompensation (HR 3.56 [95%CI 1.53–8.30]) [22].

In our cohort, we observed that liver fibrosis progression was related to well-recognized co-factors of liver damage such as consumption of alcohol and HBV co-infection. Furthermore, we found that patients with a viremic HCV infection had a 2.74 increased risk of fibrosis progression; indeed, it is known that HCV eradication

significantly reduces liver-related morbidity and mortality [23, 24]. Finally, we found that diabetes was not associated with the risk of liver fibrosis progression. These results are in contrast with those of other studies that clearly showed a link between diabetes and cirrhosis development [22, 25]. These differences can be mainly explained by the low rate of diabetes diagnosis among our HIV/HCV-co-infected patients and high rate of patients who had a baseline a FIB-4 index between 1.45 and 3.25. Indeed, it is well known that FIB-4 index had a lower accuracy for FIB-4 values inside 1.45–3.25 range [26]. The major strengths of our study are that it is based on a large cohort of HIV-infected patients with a long follow-up. Furthermore, our study is one between few studies which evaluated the role of diabetes as predictor of SLE and LRD among HIV/HCV-co-infected patients. However, our study has also some limitations that need to be taken into account. We have included a small number of patients with diabetes that can explain the lack in power to determine the role of diabetes in the liver fibrosis progression. Furthermore, we have not evaluated the impact of antiHCV-therapy on the occurrence of diabetes and SLE/LDR. Finally, a general under-reporting of liver-related complications, as with all observational studies, is possible.

In conclusion, in our cohort, viremic HCV co-infection is independently associated with diabetes. Furthermore, among HIV/HCV-co-infected population, diabetic patients showed an increased risk of SLE/LRD compared with who did not have diabetes. These results warrant further investigations to better characterize the role of diabetes as an independent prognostic factor for liver-related complications among HIV/HCV-co-infected patients.

Acknowledgments ICONA Foundation Study Group. BOARD OF DIRECTORS: A d'Arminio Monforte (President), A Antinori (Vice-President), M Andreoni, A Castagna, F Castelli, R Cauda, G Di Perri, M Galli, R Iardino, G Ippolito, A Lazzarin, GC Marchetti, G Rezza, F von Schloesser, P Viale. SCIENTIFIC SECRETARY: A d'Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cozzi-Lepri, E Girardi, S Lo Caputo, C Mussini, M Puoti, CF Perno. STEERING COMMITTEE: A Antinori, F Bai, C Balotta, A Bandera, S Bonora, M Borderi, A Calcagno, A Capetti, MR Capobianchi, A Castagna, F Ceccherini-Silberstein, S Cicalini, A Cingolani, P Cinque, A Cozzi-Lepri, A d'Arminio Monforte, A De Luca, A Di Biagio, E Girardi, N Gianotti, A Gori, G Guaraldi, G Lapadula, M Lichtner, S Lo Caputo, G Madeddu, F Maggiolo, G Marchetti, L Monno, C Mussini, S Nozza, CF Perno, C Pinnetti, M Puoti, E Quiros Roldan, R Rossotti, S Rusconi, MM Santoro, A Saracino, L Sarmati. STATISTICAL AND MONITORING TEAM: A Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano, M Macchia, A Tavelli. BIOLOGICAL BANK INMI: F Carletti, S Carrara, A Di Caro, S Graziano, F Petroni, G Protta, S Truffa. PARTICIPATING PHYSICIANS AND CENTERS: Italy A Giacometti, A Costantini, V Barocci (Ancona); G Angarano, L Monno, E Milano (Bari); F Maggiolo, C Suardi (Bergamo); P Viale, V Donati, G Verucchi (Bologna); F Castelnuovo, C Minardi, E Quiros Roldan (Brescia); B Menzaghi, C Abeli (Busto Arsizio); B Cacopardo, B Celesia (Catania); J Vecchiet, K Falasca (Chieti); A Pan, S Lorenzotti (Cremona); L Sighinolfi, D Segala (Ferrara); P Blanc, F Vichi (Firenze); G Cassola, C Viscoli, A Alessandrini, N Bobbio, G Mazarrello (Genova); M Lichtner, S Vita, (Latina); P Bonfanti, C Molteni (Lecco); A Chiodera, P Milini (Macerata); G Nunnari, G Pellicanò (Messina); A d'Arminio Monforte, M Galli, A Lazzarin, G Rizzardini, M Puoti, A Castagna, ES Cannizzo, MC Moiola, R Piolini, D Bernacchia, S Salpietro, C Tincati, (Milano); C Mussini, C Puzzolante (Modena); C Migliorino, G Lapadula (Monza); V Sangiovanni, G Borgia, V Esposito, F Di Martino, I Gentile, V Rizzo (Napoli); AM Cattelan, S Marinello (Padova); A Cascio, M Trizzino (Palermo); F Baldelli, E Schiaroli (Perugia); G Parruti, F Sozio (Pescara); G Magnani, MA Ursitti (Reggio Emilia); M Andreoni, A Antinori, R Cauda, A Cristaudo, V Vullo, R Acinapura, D Moschese, M Capozzi, A Mondì, A Cingolani, M Rivano Capparuccia, G Iaiani, A Latini, R Gagliardini, MM Plazzi, S Savinelli, A Vergori (Roma); M Cecchetto, F Viviani (Rovigo); G Madeddu, A De Vito (Sassari); B Rossetti, F Montagnani (Siena); A Franco, R Fontana Del Vecchio (Siracusa); D Francisci, C Di Giulii (Terni); P Caramello, G Di Perri, S Bonora, GC Orofino, M Sciandra (Torino); M Bassetti, A Londero (Udine); G Pellizzer, V Manfrin (Vicenza); G Starnini, A Ialungo (Viterbo).

Funding The authors received no specific funding for this work. ICONA Foundation is supported by unrestricted grants from Gilead Sciences, Janssen, Merck Sharp and Dohme, and ViiV Healthcare.

Compliance with ethical standards

Conflict of interest GO has received personal fees from Gilead Sciences and ViiV Healthcare; AC was a consultant for ViiV Healthcare, Gilead, Abbvie, BMS, Janssen, MSD; GG was a paid consultant or member of advisory boards for ViiV Healthcare, Gilead, Abbvie, BMS, Janssen, MSD; GM has been advisor for Gilead, Janssen and MSD and ViiV Healthcare and has received speakers' honoraria from BMS, Gilead, MSD, Janssen and ViiV Healthcare; ADB has been advisor for AbbVie, Gilead and MSD has received speakers' honoraria from BMS, Gilead, MSD, Janssen and ViiV Healthcare; MP was a consultant for Gilead, Abbvie, BMS, Janssen and MSD; AG has received grants and/or personal fees from BMS, Gilead, Janssen, MSD, ViiV Healthcare; ADM was a paid consultant or member of advisory boards for ViiV Healthcare, Gilead, Abbvie, BMS, Janssen, MSD. The remaining authors have no conflict of interests to disclose.

Ethical approval The ICONA study was approved by the institutional review boards or ethics committees of each clinical site.

Informed consent All patients signed an informed consent form before being enrolled at each local clinical site.

References

1. Maartens G, Celum C, Lewin SR (2014) HIV infection: epidemiology, pathogenesis, treatment, and prevention. *Lancet* 384:258–271
2. Leone S, Gregis G, Quinzan G et al (2011) Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. *Infection* 39:13–20
3. Klein MB, Rockstroh JK, Wittkop L (2016) Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. *Curr Opin HIV AIDS* 11:521–526
4. Desbois AC, Cacoub P (2017) Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review. *World J Gastroenterol* 23:1697–1711
5. d'Arminio Monforte A, Cozzi-Lepri A, Rezza G et al (2000) Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-naïve Patient. *AIDS* 14:499–507
6. Sterling RK, Lissen E, Clumeck N et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 43:1317–1325
7. Centers for Disease Control and Prevention (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep* 41:1–19
8. Lin SP, Wu CY, Wang CB et al (2018) Risk of diabetes mellitus in HIV-infected patients receiving highly active antiretroviral therapy: a nationwide population-based study. *Medicine* 97:e12268
9. Mehta SH, Brancati FL, Strathdee SA et al (2003) Hepatitis C virus infection and incident type 2 diabetes. *Hepatology* 38:50–56
10. Butt AA, Fultz SL, Kwoh CK et al (2004) Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. *Hepatology* 40:115–119
11. Tripathi A, Liese AD, Jerrell JM et al (2014) Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time. *Diabet Med* 31:1185–1193
12. Basseri B, Yamini D, Chee G et al (2010) Comorbidities associated with the increasing burden of hepatitis C infection. *Liver Int* 30:1012–1018
13. De Luca A, Lorenzini P, Castagna A et al (2017) Active HCV replication but not HCV or CMV seropositive status is associated with incident and prevalent type 2 diabetes in persons living with HIV. *J Acquir Immune Defic Syndr* 75:465–471
14. Leone S, Prosperi M, Costarelli S et al (2016) Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response. *Eur J Clin Microbiol Infect Dis* 35:1511–1520
15. Provoost A, Dramé M, Cotte L et al (2018) Risk of diabetes in HIV-infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort. *Aliment Pharmacol Ther* 48:281–289
16. Elkrief L, Rautou PE, Sarin S et al (2016) Diabetes mellitus in patients with cirrhosis: clinical implications and management. *Liver Int* 36:936–948

17. Moreau R, Delègue P, Pessione F et al (2004) Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. *Liver Int* 24:457–464
18. Yang WS, Va P, Bray F et al (2011) The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. *PLoS One* 6:e27326
19. Wang YG, Wang P, Wang B et al (2014) Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. *PLoS One* 9:e95485
20. Elkrief L, Chouinard P, Bendersky N et al (2014) Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. *Hepatology* 60: 823–831
21. Lo Re V 3rd, Kallan MJ, Tate JP et al (2014) Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. *Ann Intern Med* 160:369–379
22. Huang YW, Yang SS, Fu SC et al (2014) Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. *Hepatology* 60:807–814
23. ANRS CO13 HEPAVIH Cohort (2015) Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients. *AIDS* 29:1821–1830
24. Berenguer J, Rodríguez-Castellano E, Carrero A et al (2017) Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. *Hepatology* 66:344–356
25. Papatheodoridis GV, Chrysanthos N, Savvas S et al (2006) Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. *J Viral Hepat* 13:303–310
26. Vallet-Pichard A, Mallet V, Nalpas B et al (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. *Hepatology* 46:32–36

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.